Cardiff Oncology
CRDF
58 hedge funds and large institutions have $12.2M invested in Cardiff Oncology in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 14 closing their positions.
18% more call options, than puts
Call options by funds: $302K | Put options by funds: $255K
2.33% less ownership
Funds ownership: 20.62% → 18.29% (-2.3%)
13% less funds holding
Funds holding: 67 → 58 (-9)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
38% less capital invested
Capital invested by funds: $19.6M → $12.2M (-$7.44M)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$449K |
| 2 |
BlackRock
New York
|
+$186K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$170K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$89K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$61.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$736K |
| 2 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$652K |
| 3 |
Millennium Management
New York
|
-$466K |
| 4 |
E
Ergoteles
New York
|
-$405K |
| 5 |
Two Sigma Advisers
New York
|
-$333K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
E
51
Ergoteles
New York
| – | -$405K | -184,000 | Closed |
|
|
XT
52
XTX Topco
George Town,
Cayman Islands
| – | -$121K | -55,081 | Closed |
|
53
AQR Capital Management
Greenwich,
Connecticut
| – | -$120K | -54,580 | Closed |
|
|
MA
54
MYDA Advisors
Woodmere,
New York
| – | -$66K | -30,000 | Closed |
|
55
Two Sigma Investments
New York
| – | -$26K | -12,019 | Closed |
|
|
QT
56
Quantbot Technologies
New York
| – | -$2K | -1,300 | Closed |
|
|
NFSG
57
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$1.72K | -716 | -86% |
|
58
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -409 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$1K | -388 | Closed |
|
60
Citigroup
New York
| – | -$1K | -379 | Closed |
|
61
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -326 | Closed |
|
62
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -196 | Closed |
|
|
TFS
63
TrustCore Financial Services
Brentwood,
Tennessee
| – | +$2 | +1 | New |
|
CRDF Hedge Fund Activity: Q3 2022 in Review
58 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2022, worth a combined $12.2M — down 38% from $19.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CRDF and 5 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $449K. The largest seller was Renaissance Technologies, cutting an estimated $736K.
- 58 institutional investors held Cardiff Oncology (CRDF) as of Q3 2022, down from 67 in Q2 2022.
- Funds reported $12.2M of Cardiff Oncology stock for Q3 2022, down 38% quarter-over-quarter.
- 5 funds opened new Cardiff Oncology positions in Q3 2022 and 14 closed out, a net change of -9 holders.
- The largest Cardiff Oncology buyer in Q3 2022 was Vanguard Group, an estimated $449K added.
- The largest Cardiff Oncology seller in Q3 2022 was Renaissance Technologies, an estimated $736K sold.
Based on aggregated 13F filings for Q3 2022.